Moderna says cooperating with CDPH in probe of reports of adverse vaccine events » 12:5201/1901/19/21
Moderna stated that it…
Story temporarily locked.
Largest borrow rate increases among liquid names » 08:4501/1901/19/21
GME, WBAI, BNTX, GNOG, PLG, CVM, VUZI, IDEX, EOSE, WISH
Latest data shows the…
Latest data shows the largest indicative borrow rate increases among liquid option names include: GameStop (GME) 54.15% +23.38, 500.com (WBAI) 236.19% +14.67, BioNTech SE (BNTX) 28.64% +10.50, (GNOG) 10.42% +7.63, Platinum Group (PLG) 40.92% +6.84, Cel Sci (CVM) 71.20% +6.17, Vuzix (VUZI) 48.96% +4.89, Ideanomics (IDEX) 24.77% +3.71, B Riley Principal Merger Corp II (EOSE) 33.59% +3.68, and ContextLogic (WISH) 14.48% +3.51.
Adaptive Biotechnologies price target raised to $74 from $66 at BTIG » 06:4801/1901/19/21
BTIG analyst Mark Massaro…
Story temporarily locked.
NY Gov. asks Pfizer to directly sell COVID vaccine doses, Reuters reports » 17:1901/1801/18/21
New York Governor Andrew…
New York Governor Andrew Cuomo asked Pfizer Inc Chief Executive Albert Bourla on Monday if the state could buy COVID-19 vaccine doses directly from the U.S. drugmaker, Reuters' Kanishka Singh reports. Pfizer, however, told Reuters that such a proposal would first require approval by the U.S. Department of Health and Human Services. Reference Link
AstraZeneca, Daiichi announce FDA approval of Enhertu for gastric cancer » 12:5801/1801/18/21
AstraZeneca and Daiichi…
AstraZeneca and Daiichi Sankyo said Enhertu has been approved in the U.S. for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen. The approval by the Food and Drug Administration was based on the positive results from the randomized DESTINY-Gastric01 Phase II trial conducted in Japan and South Korea. Enhertu is approved with Boxed Warnings for interstitial lung disease or pneumonitis and embryo-fetal toxicity. This is the second indication approved for Enhertu in the U.S. following the accelerated approval for adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting based on the DESTINY-Breast01 trial.
Pakistan approves AstraZeneca COVID vaccine for emergency use, Reuters says » 17:1801/1701/17/21
AstraZeneca's COVID-19 vaccine has been approved for emergency use in Pakistan, the health minister said, making it the first coronavirus vaccine to get the green light for use in the South Asian country, Reuters' Asif Shahzad reports. Reference Link
AstraZeneca price target lowered to 10,000 GBp from 10,500 GBp at Berenberg » 14:2601/1501/15/21
Berenberg analyst Luisa…
Berenberg analyst Luisa Hector lowered the firm's price target on AstraZeneca to 10,000 GBp from 10,500 GBp and keeps a Buy rating on the shares.
Fly Intel: Top five analyst initiations » 09:5201/1501/15/21
AZN, ALLK, SKLZ, PLAN, ATI
Catch up on today's…
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. AstraZeneca (AZN) initiated with a Buy at Deutsche Bank. 2. Allakos (ALLK) initiated with a Buy at BofA. 3. Skillz (SKLZ) initiated with an Equal Weight at Wells Fargo. 4. Anaplan initiated with an Outperform rating at William Blair. 5. Allegheny Technologies (ATI) initiated with a Buy at Seaport Global. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
Aveo Pharmaceuticals announces results from portion of DEDUCTIVE trial » 08:2001/1501/15/21
Aveo Oncology (AVEO)…
Aveo Oncology (AVEO) announced the presentation of results from the Phase 1b portion of the Phase 1b/2 DEDUCTIVE clinical trial of tivozanib, Aveo's vascular endothelial growth factor receptor tyrosine kinase inhibitor, or TKI, drug candidate, in combination with Imfinzi, AstraZeneca's (AZN) human monoclonal antibody directed against programmed death-ligand 1, or PD-L1, in patients with advanced or metastatic hepatocellular carcinoma, or HCC. The results are being presented in a poster session at the 2021 American Society of Clinical Oncology Gastrointestinal, or ASCO GI, Cancers Symposium being held virtually. A total of seven patients with advanced or metastatic HCC were enrolled in the Phase 1b portion of the study, which was designed to determine the recommended Phase 2 dose and assess preliminary safety and efficacy of the tivozanib/durvalumab combination. Patients received 1.0 mg of tivozanib for 21 days followed by 7 days off therapy combined with 1500 mg of durvalumab every 28 days. The combination was well tolerated, with no dose-limiting toxicities. The combination demonstrated a 29% partial response rate and 71% disease control rate. Completion of enrollment in the ongoing Phase 2 portion of the study, which is expected to enroll up to an additional 30 subjects, is anticipated later this year.
AstraZeneca's COVISHIELD vaccine approved by Nepal, Reuters reports » 07:5301/1501/15/21
Nepal granted approval…
Nepal granted approval for AstraZeneca's COVISHIELD vaccine against the coronavirus, Reuters' Gopal Sharma and Alasdair Pal report, citing the government. The approval follows a meeting with neighboring India, a major manufacturer of the shot, the report noted. "Conditional permission has been granted for emergency use authorization of COVISHIELD vaccine against COVID-19 in Nepal," the Department of Drug Administration said. Reference Link